PL1954830T3 - Sposoby i zestawy do prognozowania przebiegu raka sutka - Google Patents

Sposoby i zestawy do prognozowania przebiegu raka sutka

Info

Publication number
PL1954830T3
PL1954830T3 PL06829113T PL06829113T PL1954830T3 PL 1954830 T3 PL1954830 T3 PL 1954830T3 PL 06829113 T PL06829113 T PL 06829113T PL 06829113 T PL06829113 T PL 06829113T PL 1954830 T3 PL1954830 T3 PL 1954830T3
Authority
PL
Poland
Prior art keywords
breast cancer
methods
patient
kits
cancer prognosis
Prior art date
Application number
PL06829113T
Other languages
English (en)
Inventor
Mathias Gehrmann
Toerne Christian Von
Original Assignee
Sividon Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics Gmbh filed Critical Sividon Diagnostics Gmbh
Publication of PL1954830T3 publication Critical patent/PL1954830T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
PL06829113T 2005-12-03 2006-11-23 Sposoby i zestawy do prognozowania przebiegu raka sutka PL1954830T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05026423 2005-12-03
EP06829113A EP1954830B1 (en) 2005-12-03 2006-11-23 Methods and kits for breast cancer prognosis
PCT/EP2006/011230 WO2007062777A1 (en) 2005-12-03 2006-11-23 Methods and kits for breast cancer prognosis

Publications (1)

Publication Number Publication Date
PL1954830T3 true PL1954830T3 (pl) 2012-03-30

Family

ID=37770891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06829113T PL1954830T3 (pl) 2005-12-03 2006-11-23 Sposoby i zestawy do prognozowania przebiegu raka sutka

Country Status (6)

Country Link
US (1) US20090130678A1 (pl)
EP (1) EP1954830B1 (pl)
AT (1) ATE530668T1 (pl)
ES (1) ES2375998T3 (pl)
PL (1) PL1954830T3 (pl)
WO (1) WO2007062777A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2036988A1 (en) * 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
EP2391962B1 (en) 2009-01-28 2016-12-21 University of Notre Dame du Lac Accelerated progression relapse test
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
WO2015123565A1 (en) * 2014-02-14 2015-08-20 The General Hospital Corporation Methods for diagnosing igg4-related disease

Also Published As

Publication number Publication date
US20090130678A1 (en) 2009-05-21
WO2007062777A1 (en) 2007-06-07
EP1954830B1 (en) 2011-10-26
EP1954830A1 (en) 2008-08-13
ES2375998T3 (es) 2012-03-08
ATE530668T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
PE20080742A1 (es) Perfil genico y procedimiento de identificacion
HK1148783A1 (zh) 用於乳房腺的預後的基因表達標記
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
MX2011004979A (es) N-cadherina:blanco para diagnosis y terapia de cancer.
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
PL1954830T3 (pl) Sposoby i zestawy do prognozowania przebiegu raka sutka
WO2013081645A3 (en) Erbb3 mutations in cancer
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
WO2006105255A3 (en) Cancer vaccines and therapeutic methods